Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

296.60 -0.77 (-0.26%)
Official Closing Price Updated: 7:00 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Bio-Rad's Management to Participate in Upcoming Investor Conferences
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad (BIO) Q2 EPS Jumps 51%
Via The Motley Fool
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
 
Via Benzinga
Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
A Preview Of Bio-Rad Laboratories's Earnings
 
Via Benzinga
Earnings Scheduled For February 13, 2025
 
Via Benzinga
The Analyst Verdict: Bio-Rad Laboratories In The Eyes Of 4 Experts
 
Via Benzinga
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
These stocks are moving in today's after hours session
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Bio-Rad Reports Second-Quarter 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
From Bio-Rad Laboratories, Inc.
Via Business Wire
5 Analysts Have This To Say About Bio-Rad Laboratories
 
Via Benzinga
Bio-Rad’s Management to Host Investor Meetings During Jefferies Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Bio-Rad Reports First-Quarter 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology 
From Biodesix, Inc.
Via GlobeNewswire
Stocks Head For Weekly Gains, US Treasury Yields Fall Below 4.5%: What's Driving Markets Friday?
Stocks are headed for weekly gains, with the Dow Jones dipping slightly and the S&P 500 and Nasdaq trading just above the flatline Friday. 
Via Benzinga
Topics Stocks
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
From Geneoscopy, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS